PDCD1 and breast cancer: This study not only provides clinical evidence that SLCs in BC could aid the personalisation of anti-PD1/PDL1 inhibition therapies, but it also emphasises that targeting the amino acid transporter, SLC7A5, along with the anti-PDL1 immunotherapy could be considered as a novel approach to synergistically enhance the therapeutic effect.